The Use of Medicines with Anti-cholinergic Properties and Their Health Impacts among Hospitalised Malaysian Geriatric Patients

Izyan A Wahab¹, Bakht Akbar¹, Zainol Akbar Zainal¹, Mohd Farizh Che Pa², Basariah Naina²

¹ Faculty of Pharmacy, Cyberjaya University College of Medical Sciences, Persiaran Bestari, Cyber 11, Cyberjaya, Selangor, Malaysia
² Pharmacy Department, Hospital Tuanku Ja'afar, Jalan Rasah, Bukit Rasah, Seremban, Negeri Sembilan, Malaysia

Submitted: 14 Oct 2018
Accepted: 24 Feb 2019
Online: 30 Apr 2019

To cite this article: Wahab IA, Akbar B, Zainal ZA, Che Pa MF, Naina B. The use of medicines with anti-cholinergic properties and their health impacts among hospitalised Malaysian geriatric patients. Malays J Med Sci. 2019;26(2):77–87. https://doi.org/10.21315/mjms2019.26.2.9

To link to this article: https://doi.org/10.21315/mjms2019.26.2.9

Abstract

Background: Studies have shown that the use of medicines with anti-cholinergic (Ach) properties can increase elderly patients’ risk of experiencing falls, confusion, and longer hospital stays (LOS). These adverse effects are preventable with appropriate intervention. Little is known about the use of medicines with Ach properties and their impact on Malaysian elderly patients. This study aimed to investigate the use of medicines with Ach properties and their impact on fall risk, confusion, and longer LOS among hospitalised elderly patients.

Methods: This study utilised a cross-sectional design and was conducted at a single centre where convenience sampling was employed to collect data from elderly patients (> 60 years) admitted to geriatric and medical wards at Hospital Tuanku Ja’afar during a 2-month period (July 2017–August 2017). Patients were excluded from this study if their hospital admission was planned for an elective procedure or if neurocognitive and hepatic impairment were diagnosed prior to the hospital admission. Medicines with Ach properties were identified and classified according to the anti-cholinergic drug scale (ADS). Univariate and multiple logistic regression statistical analyses were performed to assess its impacts on falls, confusion, and LOS.

Results: A total of 145 elderly patients with a mean age of 71.59 years old (SD = 8.02) were included in the study. Fifty-two percent of the participants were female, and the average hospital stay was 6 days (SD = 2.09). Medicines with Ach properties were administered in 62% (n = 90) of the cases. The most commonly prescribed medicine with Ach properties was furosemide (n = 59), followed by ranitidine (n = 44), warfarin (n = 23), and methylprednisolone (n = 22). Compared to patients who did not receive medicines with Ach properties, patients who received them had a significantly higher risk of falls [odds ratios (OR) = 2.61; 95%CI: 1.18, 5.78; P = 0.018], confusion (OR = 3.60; 95%CI: 1.55, 8.36; P = 0.003), and LOS (OR = 4.83; 95%CI: 2.13, 10.94; P < 0.001). Multiple comorbidities also showed a significantly increased risk of falls (OR = 3.03; 95%CI: 1.29, 7.07; P = 0.019).

Conclusion: Medicines with Ach properties had a significant impact on elderly patients’ health. Strategies for rationally prescribing medicines with Ach properties to Malaysian elderly patients need to be improved and be recognised as an important public health priority.

Keywords: anti-cholinergic, elderly, fall, confusion, length of stay
Methods

The Study Design and Site

This study was a single centre, cross-sectional retrospective study of elderly patients (age 60 or older) admitted between July 2017 and August 2017 (2 months) to the geriatric and medical wards of Hospital Tuanku Ja'afar, Seremban, which is one of Malaysia's largest publicly funded hospitals with a total of 35 wards, 1070 beds, and 20 specialist clinics. This study obtained approval from the Malaysia Research and Ethics Committee (NMRR-17-1424-36317 [IIR]).

Patient Selection Criteria and the Sample Size

Patients aged 60 or older were randomly selected if they had a complete medical record that included a demographic profile, the reason for hospitalisation, and the prescribed medications. Patients were excluded from this study if they had been diagnosed with a cognitive-psychiatry disease, stroke, or hepatic encephalopathy prior to the hospital admission. Patients admitted for elective surgery and investigational procedures were also excluded. The minimum sample size was calculated using an established sample size formula (14) from previous studies where $P = 0.5$ (3, 5). A minimum of 132 patients was required for this study. Hospital Tuanku Ja'afar has a bed occupancy rate (BOR) of 98% for medical wards. We used convenience sampling to select our elderly patients.

Data Collection

Trained clinical researchers collected the following data from the selected patients' medical records upon admission to the hospital's geriatric and medical wards. Medicines with Ach properties were identified and classified according to the Ach load level using the anti-cholinergic drug scale (ADS) (15). This scale has been validated for medicines that have a significant association with serum Ach activity (15) and predicted Ach drug-related adverse events (16). The scales are as follows: Level 0 = no known Ach activity; Level 1 = potentially Ach activity as evidenced by receptor binding studies; Level 2 = Ach adverse events sometimes noted, usually at excessive doses; and Level 3 = markedly Ach. A list of medicines and their levels is included in Appendix 1. Adverse outcomes,
such as falls and confusion (or delirium), as well as the LOS, were identified and extracted from patients’ medical records from admission until discharge. A previous history of these outcomes prior to admission was also identified and extracted. The LOS for all selected patients was counted from the first day of the hospital admission until discharge.

Data Analysis

Descriptive statistics were used to summarise patients’ demographic variables. Continuous data were presented using means and standard deviations, and categorical data were presented as numbers and percentages. The prevalence of medicines with Ach properties was quantified over the two-month period, which was from 1 July 2017 to 31 August 2017. A univariate analysis was performed using a chi-squared test for categorical data. Variables used in the univariate analysis were age (0: 60–69 years, 1: ≥ 70 years), gender (0: man, 1: woman), smoking (1: Yes, 0: No), alcohol intake (1: Yes, 0: No), number of medicines prescribed (0: < 5 medicines, 1: ≥ 5 medicines), comorbidities (1: Yes, 0: No), and Ach medicines prescribed (1: Yes, 0: No). Multiple logistic regressions were used and included the following variables; age, gender, comorbidities, number of medicines use, smoking, alcohol intake, and Ach medicine use to determine the predictors of adverse outcomes, which were fall, confusion, and longer LOS. All statistical analyses were undertaken using Stata v.12 (TX: StataCorp LP). The results are presented as odds ratios (OR) with 95% confidence intervals and P-values.

Results

Sample Characteristics

A total of 145 patients were included in this study. Of these, 52% (n = 75) were female, with a mean age of 71.59 years (SD = 8.02) (Table 1). Malay (54%, n = 79) was the most prevalent ethnicity in this study sample, followed by Chinese (28%, n = 28) and Indian (17%, n = 25). Most of the patients’ hospital admissions were due to symptoms, signs, and abnormal clinical and laboratory findings (72.4%, n = 105).

| Table 1. Characteristics of sample: Overall and by Ach use (n = 145) |
|---------------------------------------------------------------|
| **Overall** (n = 145) | **User of Ach** (n = 90) | **Non-user of Ach** (n = 55) | X²-statistics (df)* | P-value* |
|----------------------|-------------------------|-----------------------------|---------------------|----------|
| Gender               |                         |                             |                     |          |
| Male                 | 70                      | 48.3                        | 45                  | 50.0     | 0.282 (1) | 0.595 |
| Female               | 75                      | 51.7                        | 45                  | 50.0     | 0.030 (1) | 0.865 |
| Age (Mean (SD) = 71.51 (8.02) |                     |                             |                     |          |
| 60–69                | 67                      | 46.2                        | 39                  | 43.3     | 0.788 (1) | 0.375 |
| ≥ 70                 | 78                      | 53.8                        | 51                  | 56.7     | 0.162 (1) | 0.687 |
| Smoking              |                         |                             |                     |          |
| No                   | 126                     | 86.9                        | 79                  | 87.7     | 0.162 (1) | 0.687 |
| Yes                  | 19                      | 13.1                        | 11                  | 12.3     | 0.004 (1) | 0.948 |
| Alcohol intake       |                         |                             |                     |          |
| No                   | 134                     | 92.4                        | 84                  | 93.3     | 0.286 (1) | 0.593 |
| Yes                  | 11                      | 7.6                         | 6                   | 6.7      | 0.004 (1) | 0.948 |
| Comorbidities        |                         |                             |                     |          |
| No                   | 39                      | 26.9                        | 20                  | 22.2     | 2.637 (1) | 0.104 |
| Yes                  | 106                     | 73.1                        | 70                  | 77.8     | 0.256 (1) | 0.610 |
| Number of medicines  |                         |                             |                     |          |
| < 5                  | 68                      | 46.9                        | 29                  | 32.2     | 20.516 (1) | <0.001* |
| ≥ 5                  | 77                      | 53.1                        | 61                  | 67.8     | 16                  | 29.1     |

*Chi-square test for independence, P <0.05 for significance level
followed by digestive system problems (12.4%, \( n = 18 \)) (Table 2). Almost half of the patients had a history of falls (45%, \( n = 65 \)); however, most of them had no history of fractures (95%, \( n = 137 \)). For secondary diagnoses during the hospital stay, most of our sample had cardiovascular diseases (87%, \( n = 127 \)). Of these, hypertension (32%, \( n = 41 \)) and heart failure (30%, \( n = 30 \)) were the most common diagnoses. The mean length of hospital stay was 6 days (SD = 2.09).

### The Utilisation of Medicines with Ach Properties

This study reveals that more than half of the patients took at least one medicine with Ach properties (62%, \( n = 90/145 \)) during their hospitalisation, whereas 37% (\( n = 54/145 \)) took a single medicine with Ach properties, and 25% (\( n = 36/145 \)) were prescribed multiple medicines with Ach properties. Compared to non-users, individuals on Ach medicines were more likely to be aged > 70 years old and smoke tobacco, as well as have multiple comorbidities and more than five medicines in their regimen (Table 1). A higher number of medicines was associated with Ach medicine use. Twenty-one types of medicines with Ach properties were used by the geriatric patients (Table 3), for a total of 260 frequency exposures. Based on the ADS, the most common utilisation of medicines with Ach properties was Level 1-mild (81%, \( n = 209/260 \)), followed by Level 2-moderate (17%, \( n = 44/260 \)) and Level 3-severe (2.7%, \( n = 7/260 \)).

Most of the medicines with Ach properties are cardiovascular system medications, such as furosemide (\( n = 59 \)), warfarin (\( n = 23 \)), digoxin (\( n = 13 \)), and isosorbide dinitrate (\( n = 13 \)). Respiratory medications were the second most commonly used medication with Ach properties. Among these respiratory medicines are prednisolone (\( n = 22 \)), hydrocortisone (\( n = 16 \)), theophylline (\( n = 11 \)), and diphenhydramine (\( n = 6 \)). All these medicines are ADS Level 1.

Medication with Ach properties acting on the gastrointestinal system was the third most commonly used (i.e., ranitidine \( n = 44 \)). This is the only ADS Level 2 medication used by the study patients. Hence, out of 145 patients, 44 (30%) were prescribed ranitidine. Only two ADS Level 3 medicines (i.e., diphenhydramine and chlorpheniramine) were used, by a total of 7 geriatric patients.

### Predictors of Falls, Confusion, and Length of Hospital Stay (LOS)

This study used correlation coefficient analysis to check for a multicollinearity threat. The correlation coefficient results showed the highest correlation coefficient is 0.3762, which is less than the 0.9000 cut-off point. Hence, there is no multicollinearity issue present in the study. The Hosmer-Lemeshow test results (Table 4) for all three models indicate that the \( P \)-values were not significant and that the three models’ fit is good.

The multiple regression analysis identified several patient factors associated with a high risk of falls, confusion, and LOS (Table 4). Medicines with Ach properties were significantly associated with a high risk of falls (OR = 2.61; 95%CI: 1.18, 5.78; \( P = 0.018 \)), confusion (OR = 3.60; 95%CI: 1.55, 8.36; \( P = 0.003 \)), and LOS (OR = 4.83; 95%CI: 2.13, 10.94; \( P = < 0.001 \)). Comorbidities were also significantly associated with falls (OR = 3.03; 95%CI: 1.30, 7.08; \( P = 0.01 \)). Gender, age, smoking, alcohol intake, and the number of medicines prescribed were not associated with any of the adverse outcome measures.

### Discussion

This paper provides a ‘snapshot’ of the pattern of Ach medicine use among geriatric patients at one hospital in Malaysia. The prevalence of Ach medicine use was high in

| Table 2. Cause of hospital admission of elderly patients samples (\( n = 145 \)) |
|-----------------------------------------------|-------------|
| **Cause of Admission**                        | **Frequency (%)** |
| Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | 105 (72.4) |
| Diseases of the digestive system               | 18 (12.4)   |
| Certain infectious and parasitic diseases      | 9 (6.2)     |
| External causes of morbidity and mortality     | 8 (5.5)     |
| Diseases of the circulatory system             | 5 (3.5)     |
Table 3. Prescribed medicines with Ach properties

| Medicine              | ADS Level | Number of Patients |
|-----------------------|-----------|-------------------|
| Furosemide            | 1         | 59                |
| Ranitidine            | 2         | 44                |
| Warfarin              | 1         | 23                |
| Methylprednisolone    | 1         | 22                |
| Hydrocortisone        | 1         | 16                |
| Digoxin               | 1         | 13                |
| Isosorbide dinitrite  | 1         | 13                |
| Tramadol              | 1         | 13                |
| Theophylline          | 1         | 11                |
| Ampicillin            | 1         | 11                |
| Vancomycin            | 1         | 7                 |
| Piperacillin          | 1         | 6                 |
| Diphenhydramine       | 3         | 6                 |
| Alprazolam            | 1         | 4                 |
| Lorazepam             | 1         | 4                 |
| Morphine              | 1         | 3                 |
| Diazepam              | 1         | 1                 |
| Dexamethasone         | 1         | 1                 |
| Captopril             | 1         | 1                 |
| Clindamycin           | 1         | 1                 |
| Cholorpheniramine     | 3         | 1                 |

Table 4. Association of fall, confusion and LOS with tested variables

| Variables                  | Fall          | Confusion     | LOS            |
|----------------------------|---------------|---------------|----------------|
|                            | OR (95%CI)    | P-value       | OR (95%CI)     | P-value       | OR (95%CI) | P-value |
| Age                       | 1.06 (0.52–2.16) | 0.864 | 1.44 (0.70–2.97) | 0.320 | 0.98 (0.47–2.02) | 0.952 |
| Gender                    | 0.70 (0.33–1.45) | 0.335 | 0.74 (0.35–1.57) | 0.427 | 0.56 (0.26–1.18) | 0.128 |
| Comorbidities             | 3.03 (1.30–7.08)* | 0.010* | 1.46 (0.63–3.38) | 0.380 | 0.56 (0.25–1.29) | 0.175 |
| Number of medicines use   | 0.72 (0.34–1.56) | 0.410 | 0.78 (0.36–1.69) | 0.524 | 1.10 (0.51–2.38) | 0.808 |
| Smoking                   | 0.63 (0.21–1.90) | 0.410 | 1.55 (0.50–4.80) | 0.444 | 0.75 (0.24–2.36) | 0.622 |
| Alcohol intake            | 1.21 (0.31–4.71) | 0.788 | 0.32 (0.06–1.66) | 0.176 | 0.47 (0.11–1.94) | 0.295 |
| Anticholinergic medicine use | 2.61 (1.18–5.78)* | 0.018* | 3.60 (1.55–8.37)* | 0.003* | 4.83 (2.14–10.94)* | < 0.001* |
| Hosmer and Lemeshow (Prob > chi2) | 0.521 | 0.213 | 0.754 |

*Statistically significant
and without dementia (27). The study found that the level-1 Ach medicines contributed to the highest Ach load where cardiovascular medicines were the most commonly prescribed including furosemide, warfarin and isosorbide mononitrate. Cumulative Ach medicines use have shown to cause adverse drug reactions (28) and increase hospitalisation and mortality in the elderly (9). Our study did not measure the cumulative effect of each level of Ach medicine on falls, confusion, and LOS. However, given the findings of our study, further consistency of results can be expected because a higher number of medicines used was associated with Ach medicine intake (Table 1). This result is also supported by another study where the number of medicines used was a predictor of a higher Ach burden (29). The relatively large number of Ach medicines categorised as Level 1 or low Ach potency needs to be made communicated to clinicians because the risk of falls, confusions, and longer LOS for one Level 3 Ach medicine may be the same as when multiple Level 1 Ach medicines are used.

Although only a handful of Levels 2 and 3 Ach medicines were prescribed in this study sample (i.e., ranitidine, diphenhydramine, and chlorpheniramine), caution should be exercised because these medicines can easily alter elderly patients’ mental status, especially in the emergency department (ED) where confusion is a common presentation and the chief complaint among elderly patients (30). A study involving 426 patients in the United States found that diphenhydramine administration during hospitalisation resulted in an increased risk of delirium symptoms, hallucinations, and altered consciousness (31).

Efforts to reduce the Ach medicines use in older people is currently underway. Reducing the dose or discontinuing Ach medicines are some of the awareness and implementation protocols currently being executed by clinical pharmacists (32–34). Other tools and measures are also being investigated to improve medication use among elderly patients in various settings (35–37). From the perspective of healthcare practitioners, drug developers, and regulators, establishing a common ground of understanding regarding pertinent information about older people for rational prescribing may still be lacking, and further collaboration among these stakeholders is highly recommended to improve prescribing in this population (38). Regardless of the various proposed strategies, no single method...
or approach could guarantee medication safety in older populations at any one time. Medication safety in older people will require simultaneous changes and optimisation in information handling, drug distribution and education, prescription, follow-up routines, and tools (39).

In this study, we did not make adjustments to account for potential confounders that could occur when there are differences between the Ach medicine exposed and non-exposed groups. This study shows that there are no significant differences between the two groups (Table 1), and the variables tested are not related to each other in the linear regression models. The results of this study, however, cannot be generalised to all geriatric patients in Malaysia because only a few outcomes were assessed within a short period of time, and we did not control for the dose and duration of Ach medicine use. Other factors that could contribute to falls, confusions and longer LOS, such as low bone mineral density, dehydration, and renal function status, were not taken into consideration in this study. Future work is required to include more factors and investigate Ach medicine doses that could be safely used in the elderly when no alternatives can be recommended.

Conclusion

A significant percentage of our sample of elderly patients were exposed to Ach medicines. The use of medicines with Ach properties was associated with falls, confusion, and longer LOS. Level 1 Ach medicines were commonly used in our sample. Healthcare providers are highly encouraged to be more cautious in prescribing medicines to older, hospitalised patients. Since many over-the-counter and prescribed medicines have Ach properties, a continuous effort by all healthcare providers and authorities to educate older people and their caretakers should be established as an important public health priority.

Acknowledgements

We would like to thank Hospital Tuanku Ja’afar for providing the data used in this study. We would also like to thank the Director General of Health, Malaysia for his permission to publish this article. The study results, discussion, and conclusion are the authors’ and do not represent the opinion of the Ministry of Health, Malaysia.
References

1. Salahudeen MS, Duffull SB, Nishtala P.S. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. *BMJ Geriatrics*. 2015;**15**(1):31. https://doi.org/10.1186/s12877-015-0029-9

2. Woodman RJ, Roojii SE. Measure of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postcholinergic mortality in older hospitalized patients with hip fractures. *Am J Geriatr Psychiatry*. 2013;**21**(8):785–793. https://doi.org/10.1016/j.jagp.2013.01.012

3. Crispo JAG, Willis AW, Thibault DP, Fortin Y, Hays HD, McNair DS, et al. Associations between anticholinergic burden and adverse health outcomes in Parkinson disease. *PLoS One*. 2016;**11**(3):1–15. https://doi.org/10.1371/journal.pone.0150621

4. Chatterjee S, Aparasu RR, Carnahan RM, Johnson ML, Chen H. Prevalence of anticholinergic medication use among elderly nursing home residents with depression. *The International Society for Pharmacoeconomics and Outcomes Research*. 2014;**17**(3):A211. https://doi.org/10.2165/11584430-000000000-00000

5. Landi F, Aquila GD, Collamati A, Martone AM, Zuliani G, Gasperini B, et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. *Journal of the American Medical Directors Association*. 2014;**15**(11):825–829. https://doi.org/10.1016/j.jamda.2014.08.002

6. Alagiakrishnan K, Wiens CA. An approach to drug induced delirium in the elderly. *BMJ Postgrad Med Journal*. 2004;**80**(945):388–394. http://dx.doi.org/10.1136/pgmj.2003.017236

7. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident of dementia. A prospective cohort study. *JAMA Intern Med*. 2015;**175**(3):401–407. https://doi:10.1001/jamainternmed.2014.7663

8. Ruxton K, Woodman RJ, Mangoni A. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. *Br J Clin Pharmacol*. 2015;**80**(2):209–220. https://doi.org/10.1111/bcp.12617

9. Gnjidic D, Hilmer SN, Hartikainen S, Tolppanen A-M, Taipale H, Koponen M, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer’s disease: a national population cohort study. *PLoS One*. 2014;**9**(1):1–8. https://doi.org/10.1371/journal.pone.0083224

10. Ancelin ML, Artero S, Portet FS, Dupuy A-M, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. *BMJ*. 2006;**332**:455–459. https://doi.org/10.1136/bmj.38740.439664.DE

11. Maarten W, Therese K, Monique E, Vaes B, Dalleur O, Degryse J, et al. Anticholinergic exposure in a cohort of adults aged 80 years and over: associations of the MARANTE scale with mortality and hospitalization. *Basic Clin Pharmacol Toxicol*. 2017;**120**(6):591–600. https://doi.org/10.1111/bcpt.12744

12. Kersten H, Wyller TB. Anticholinergic drug burden on older people’s brain – how well is it measured? *Basic Clin Pharmacol Toxicol*. 2014;**120**(6):591–600. https://doi.org/10.1111/bcpt.12744

13. Jia JP, Jia JM, Zhou WD, Xu M, Chu CB, Yan X, et al. Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia. *Chin Med J*. 2004;**117**(8):1161–1164.

14. Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculations in medical studies. *Gastroenterol Hepatol Bed Bench*. 2013;**6**(1):14–17.

15. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. *J Clin Pharmacol*. 2006;**46**(12):1481–1486. https://doi.org/10.1177/0091270006292126
Original Article | Use of medicines with anti-cholinergic properties among geriatric

16. Lampela P, Lavikainen P, Garcia-Horsman JA, Bell S, Huupponen R, Hartikainen S. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population based study. *Drugs Aging*. 2013;30(5):321–330. https://doi.org/10.1007/s40266-013-0063-2

17. O’Donnell LK, Gnjidic D, Nahas R, Bell JS, Hilmer SN. Anticholinergic burden: considerations for older adults. *Journal of Pharmacy Practice and Research*. 2017;46(1):67–77. https://doi.org/10.1002/jppr.1303

18. Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergic: a clinical review. *Clinic Interv Aging*. 2009;4:225–233. https://doi.org/10.2147/CIA.S5358

19. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. *J Am Geriatric Soc*. 2011;59(8):1477–1483. https://doi.org/10.1111/j.1532-5415.2011.03491.x

20. Thomas C, Hesterman U, Kopiz J, Plaschke K, Oster P, Driessen M, et al. Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and with-out delirium. *BMC Neuroscience*. 2008;9:1–10. https://doi.org/10.1186/1471-2202-9-86

21. Ministry of Health. Malaysian statistics on medicines 2011–2014. Pharmaceutical Services Programme, Ministry of Health; 2017.

22. Torstensson M, Hansen AH, Katja L, Teresa Sara HJ, Sahlberg M, Anderson C, et al. Danish register-based study on the association between specific cardiovascular drugs and fragility fractures. *BMJ Open*. 2015;5(12):e009522. https://doi.org/10.1136/bmjopen-2015-009522

23. Margolis KL, Buchner DM, LaMonte MJ, Zhang Y, Di C, Rillamas-Sun E, et al. Hypertension treatment and control and risk of falls in older women. *J Am Geriatr Soc*. 2019;67(1):1–8. https://doi.org/10.1111/jgs.15732

24. Jacob SA, Ibrahim MIM, Mohammed F. Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia. *Ment Health Fam Med*. 2013;10(1):37–43.

25. Van Doorn C, Gruber-Baldini AL, Zimmerman S, Hebel JR, Port CL, Baumgarten M, et al. Dementia as a risk factor for falls and fall injuries among nursing home residents. *J Am Geriatr Soc*. 2003;51(9):1213–1218. https://doi.org/10.1046/j.1532-5415.2003.51040.x

26. Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. *JAMA*. 1987;257(11):1492–1495. https://doi.org/10.1001/jama.1987.03390110068028

27. Karen EM, Karen PK, Dimity P, Williams EJ, Marley J, Disler P, et al. Impact of multiple low level anticholinergic medications in anticholinergic load of community-dwelling elderly with and without dementia. *Drugs and Aging*. 2014;32(2):159–167. https://doi.org/10.1007/s40266-014-0230-0

28. Tune LE. Anticholinergic effects of medications in elderly patients. *J Clin Psychiatry*. 2001;62(Suppl 21):11–14.

29. Parkinson L, Magin PJ, Thomas A, Byles JE, Caughley GE, Etherton-Beer C, et al. Anticholinergic burden in older woman: not seeing the wood for the trees? *Med J Aust*. 2015;202(2):91–94. https://doi.org/10.5694/mja14.00336

30. Jin HH, Scott TW. Altered mental status in older emergency department patients. *Clinical Geriatric Medicine*. 2013;29(1):101–136. https://doi.org/10.1016/j.cger.2012.09.005

31. Joseph VA, Linda SLS, Sharon KI. Cognitive and other adverse effects of diphenhydramine use in hospitalised older patients. *Arch Intern Med*. 2001;161(17):2091–2097.

32. Ailabouni N, Manqin D, Nishtala PS. Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities. *BMJ Open*. 2017;7(4):e013800. https://doi.org/10.1136/bmjopen-2016-013800

33. Ailabouni N, Manojn D, Nishtala PS. Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities. *BMJ Open*. 2017;7(4):e013800. https://doi.org/10.1136/bmjopen-2016-013800

34. Vanessa M, Emily W, Alan JP, Katie H, Arvind R, Barry J. Deprescribing medicines in the acute setting to reduce the risk of falls. *European Journal of Hospital Pharmacy*. 2017;24(1):10–15. https://doi.org/10.1136/ehjpharm-2016-001003
34. Parasad SN, Mohammed SS, Sarah NH. Anticholinergics: theoretical and clinical overview. Expert Opin Drug Saf. 2016;15(6):753–768. https://doi.org/10.1517/14740338.2016.1165664

35. Farhad P, Heinrich B, Helmut F, Christel W, Christina T, Alexandra K-T, et al. Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments. Eur J Clin Pharmacol. 2018;74(3):339–347. https://doi.org/10.1007/s00228-017-2383-3

36. Virginie D, Elodie JB, Pierre KS, Christelle M. A multi-center, randomized, controlled trial to assess the efficacy of optimization of drug prescribing in an elderly population, at 18 months of follow-up, in the evolution of functional autonomy: the OPTIM study protocol. BMC Geriatr. 2017;17(1):195. https://doi.org/10.1186/s12877-017-0600-7

37. Susan B, Kandarp T, Vanessa M, Bryony DF, Derek B. Evaluation of My Medication Passport: a patient-completed aide-memoire designed by patients, for patients, to help towards medicines optimisation. BMJ Open. 2014;4(8):e005608. http://dx.doi.org/10.1136/bmjopen-2014-005608

38. Beers E, Egberts TCG, Leufkens HGM, Jansen PAF. The views of healthcare professionals, drug developers and regulators on information about older people needed for rational drug prescription. PLoS One. 2013;8(8):e72060. https://doi.org/10.1371/journal.pone.0072060

39. Swedish Council on Health Technology Assessment. How can drug consumption among the elderly be improved?: a systematic review. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2009. Report No. 193.
**Appendix 1.** Drugs classification based on ADS levels (available in Hospital Tuanku Ja’afar)

| Level 3 Drugs | Level 2 Drugs | Level 3 Drugs |
|---------------|---------------|---------------|
| Amitriptyline | Clozapine     | Meclizine     |
| Atropine      | Diphenhydramine | Oxybutynin   |
| Chlorpheniramine | hydroxyzine | Promethazine |
| Chlorpromazine | Imipramine    | Tolterodine   |
| Clomipramine  |               |               |
| Level 2 Drugs | Ranitidine    |               |
| Carbamazepine |               |               |
| Level 3 Drugs |               |               |
| Alprazolam    | Fluoxetine    | Nifedipine    |
| Amantadine    | Fluphenazine  | Olanzapine    |
| Ampicillin    | Fluticasone-salmeterol | Oxycodone |
| Azathioprine  | Fluvoxamine   | Pancuronium   |
| Bromocriptine | Furosemide    | Phenelzine    |
| Captopril     | Gentamicin    | Piperacillin  |
| Clindamycin   | Hydralazine   | Prednisolone  |
| Clonazepam    | Hydrocortisone| Prochlorperazine |
| Cycloserine   | Isosorbide    | Sertralline   |
| Cyclosporine  | Isosorbide dinitrate | Theophylline |
| Dexamethasone | Isosorbide mononitrate | Tramadol |
| Diazepam      | Loperamide    | Triamcinolone |
| Diphenoxylate | Midazolam     | Warfarin      |
| Fentanyl      | Morphine      |               |